Investors

Able Partners is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Aja Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Ambria Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Family office and investment group with repeated financing participation in psychedelic drug-development companies, including atai Life Sciences.

Ark Invest is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

BTIG is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

BVF Partners is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Berenberg is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Bicycle Day Ventures is tracked as a syndicate/network investor that may channel capital into psychedelic and adjacent mental-health ventures.

BlackRock is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Blackhawk Growth Corp is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Boxer Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Canaccord Genuity is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Cantor Fitzgerald is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Catalio Capital Management is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Cowen is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Deerfield is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

EF Hutton is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Empath Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Evercore is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Evolve Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Future Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Gaingels is tracked as a syndicate/network investor that may channel capital into psychedelic and adjacent mental-health ventures.

H.C. Wainwright & Co. is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Hercules Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Psychedelic-focused venture capital firm investing in drug development, care delivery, and platform infrastructure across the sector.

JLS Fund is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Jefferies is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Johnson & Johnson is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Kevin O'Leary is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

Leafy Tunnel is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Levitee Labs is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

MBX Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Matt Mullenweg is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

Maxim Group is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Mike Novogratz is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

Mission Club is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

Morgan Stanley is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Negev Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Neo Kuma is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Impact-oriented investment fund focused on psychedelic medicine and consciousness-related innovation with explicit sector-specific framing.

OMX Venture is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Oppenheimer is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Orbimed Advisors is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Origin Therapeutics is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Oscillate is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Otsuka is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Venture capital fund focused on psychedelic and broader mental health innovation, with portfolio activity across therapeutics and enabling infrastructure.

Angel investor and entrepreneur with publicly documented participation in atai Life Sciences financing rounds tied to psychedelic drug-development.

Phyto Partners is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Presight Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Prime Movers Lab is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Venture investment platform focused on psychedelic and mental health innovation with emphasis on clinically actionable models.

Psych Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Pura Vida Investments is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

QC Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

RA Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

RTW Venture Fund is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Roth Capital is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Route 66 Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Stifel is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Subversive Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Tabula Rasa Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

The Conscious Fund is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Tim Ferriss is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

Venrock Healthcare Capital Partners is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Vine Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

What If Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Y Combinator is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

re.Mind is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.